- ►diabetesjournals.org ML Becker, LE Visser, RHN van Schaik, A … - Diabetes, 2009 - Am Diabetes Assoc OBJECTIVE— Metformin, an oral glucose-lowering drug, is taken up in
hepatocytes by the organic cation transporter (OCT) 1 and in renal epithelium by
OCT2. In these cells, the multidrug and toxin extrusion (MATE) 1 protein, ... Cited by 8 - Related articles - All 4 versions
- ►diabetesjournals.org K Zhou, LA Donnelly, CH Kimber, PT Donnan, … - Diabetes, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS The Diabetes Audit and Research in Tayside Scotland
(DARTS) database includes prescribing and biochemistry information and clinical
phenotypes of all patients with diabetes within Tayside, Scotland, from ... Cited by 5 - Related articles - All 3 versions
MV Tzvetkov, SV Vormfelde, D Balen, I Meineke, … - CliniCal pharmaCology & TherapeuTiCs, 2009 - crosbi.znanstvenici.hr Interindividual variations in the pharmacokinetics of drugs may be caused by
genetic variations in biotransformation and transmembrane transport.1–5
Metformin is a very important oral antidiabetic drug used in the treatment ... Cited by 2 - Related articles - View as HTML - All 8 versions
AT Nies, H Koepsell, S Winter, O Burk, K … - Hepatology, 2009 - interscience.wiley.com An important function of hepatocytes is the biotransformation and elimination of
various drugs, many of which are organic cations and taken up by organic cation
transporters (OCTs) of the solute carrier (SLC) family 22. Because ... Cited by 2 - Related articles - All 2 versions
ML Becker, LE Visser, RHN van Schaik, A … - The Pharmacogenomics Journal, 2009 - nature.com The organic cation transporter 1, encoded by the SLC22A1 gene, is responsible
for the uptake of the anti-hyperglycaemic drug, metformin, in the hepatocyte. We
assessed whether a genetic variation in the SLC22A1 gene is associated with ... Cited by 4 - Related articles - All 3 versions
IS Song, HJ Shin, EJ Shim, IS Jung, WY Kim, … - Clinical Pharmacology & Therapeutics, 2008 - nature.com Genetic variants of the organic cation transporter 2 (protein, OCT2; gene,
SLC22A2) were evaluated for their contribution to the variations in the
pharmacokinetics of metformin, especially to its renal elimination. Genetic ... Cited by 20 - Related articles - All 5 versions
H Takane, E Shikata, K Otsubo, S Higuchi, I … - Pharmacogenomics, 2008 - Future Medicine Considerable interindividual variabilities in clinical efficacy and adverse
events are sometimes recognized in the treatment of Type 2 diabetes mellitus
with oral antihyperglycemic drugs. Metformin is the most commonly used ... Cited by 14 - Related articles - BL Direct - All 4 versions
ZJ Wang, OQP Yin, B Tomlinson, MSS Chow - Pharmacogenetics and Genomics, 2008 - journals.lww.com Purpose Genetic polymorphisms of organic cation transporter 2 (OCT2) have been
recently described, but their genotype–phenotype relationship in humans is
unknown. We performed this study to (i) characterize genetic variations of ... Cited by 11 - Related articles - All 4 versions
MK CHOI, IS SONG - Drug Metabolism and Pharmacokinetics, 2008 - J-STAGE Inje University College of Medicine, #633-165 Gaegum-dong, Jin-gu, Busan
614-735, Korea. Tel. ＋8251-890-6412, Fax. ＋8251-893-1232, Email:
issong＠inje.ac.kr This study was supported by a grant of the Korea health ... Cited by 7 - Related articles - All 2 versions
